27 Apr 2020
Posted in Pharma
Clinical trials evaluating pain and mental health conditions are the neurology indications affected most by COVID-19, says GlobalData
Clinical trials evaluating pain and mental health conditions are the neurology indications most affected by the ongoing COVID-19 pandemic, says GlobalData, a leading data and analytics company.
A combination of lockdown measures as well as the need to re-prioritize existing healthcare resources in a hospital setting are all essential steps being taken to combat the virus. However, from an industry perspective, companies are needing to adapt their clinical trials in order to adhere to social distancing guidelines and to ensure that risks to clinical trial participants associated with COVID-19 are minimized during such operations.
Vinie Varkey, Senior Neurology & Ophthalmology Analyst at GlobalData, comments: “The pharma industry has been mobilised to fight against the pandemic and rightly so. However these critical efforts also mean that operations related to non-COVID19 indications are affected to an extent. An example is the impact of the pandemic on clinical trials. As of 15th April 2020 GlobalData’s clinical trials database confirms that a total of 81 clinical trials with a definite neurology indication have been impacted by the pandemic.
“Indications such as pain and mental health conditions together account for 40% of all these trials. Mental health conditions covered by these trials include those related to depression, psychiatric disorders, psychosis, and schizophrenia, and other unspecified disorders. Coming in at the third most affected indication is addiction, which account for 11% of the total trials evaluating neurology indications. Addictions include those related to alcohol, opium and nicotine.”